- GlobeNewswire•4 days ago
Representatives from Actinium will attend to promote awareness among attending physicians and health professionals on Iomab-B and the SIERRA trial NEW YORK, Jan. 20, 2017-- Actinium Pharmaceuticals, Inc., ...
- GlobeNewswire•6 days agoActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer
Berger brings 20 years of drug development experience highlighted by the FDA approvals of Mylotarg ® for acute myeloid leukemia, the only drug approved in AML in several decades, and Tykerb ® for breast ...
- GlobeNewswire•14 days ago
NEW YORK, Jan. 10, 2017-- Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh ...
ATNM : Summary for Actinium Pharmaceuticals, Inc. - Yahoo Finance
Actinium Pharmaceuticals, Inc. (ATNM)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.96 - 1.02|
|52 Week Range||0.86 - 2.45|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|